Would you ever switch capmatinib to tepotinib or vice versa for patients with NSCLC with MET ex 14 skipping mutation who are responding to treatment but with ongoing edema despite dose reductions?

The MET TKIs universally cause edema that progressively develops and persists with these drugs. Unfortunately, switching from capmatinib to tepotinib or vice versa will not improve the peripheral edema. Symptomatic treatment and dose interruption or reduction are the best management strategies.

I have had several patients on a MET TKI who developed significant peripheral edema. Fortunately, they have done very well on low dose furosemide and have been able to continue on the drug.

I agree with Dr. @Dr. First Last that the to drugs have similar MOA and peripheral edema is a common AE. Theoretically, switch should not make a difference but I have switched from capmatinib to tepotoinib in clinic for uncontrollable AEs including peripheral edema (using recommended strategies) and...